Daniel P. Petrylak, MD

Yale University Cancer Center

New Haven, Connecticut

Daniel P. Petrylak, MD, leads the genitourinary cancers medical oncology team at Smilow Cancer Hospital as director of the genitourinary cancer research group, professor, and co-director of the Cancer Signaling Network program. Dr. Petrylak joined Yale from Herbert Irving Cancer Center at Columbia University Medical Center with New York-Presbyterian Hospital, where he served as Professor of Medicine (Medical Oncology) and Urology and began his appointment in September of 2012. Dr. Petrylak is a member of the American Association for Cancer Research (AACR), American Society for Clinical Oncology (ASCO), American College of Physicians (ACP), American Association for the Advancement of Science (AAAS), American Urological Association (AUA), and the Southwest Oncology Group (SWOG). After serving for more than 20 years as the advanced bladder chair for SWOG, Dr. Petrylak is now the Vice Chair of the Genitourinary Committee. He additionally has led multiple national and international studies in prostate and bladder cancer.

Dr. Petrylak’s research interests span both prostate and bladder cancer. He led an investigator-initiated trial of docetaxel and estramustine in castration resistant prostate cancer. The results of this study supported a phase 3 trial of this combination in SWOG led by Dr. Petrylak, which in turn, supported the FDA approval of docetaxel for castration resistant prostate cancer. This was one of the first two trials to demonstrate a survival benefit in this state of disease. Dr. Petrylak has also been instrumental in the development of immunotherapy and targeted therapies for refractory bladder cancer. His work with Enfortumab Vedotin has supported the accelerated and full FDA approval of this drug.

Dr. Petrylak received his undergraduate degree from Columbia College and his medical degree from Case Western University School of Medicine. He completed his internship and residency at Albert Einstein College of Medicine and his fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center. He has authored more than 200 peer-reviewed articles and book chapters on prostate and bladder cancer research outcomes.

Talks by Daniel P. Petrylak, MD

Targeted Therapy for the Treatment of Advanced/Metastatic Urothelial Cancer

Posted by Daniel P. Petrylak, MD | Apr 2019

Daniel P. Petrylak, MD, discusses current evidence on various pathways to target when treating metastatic urothelial cancer. He reviews agents targeting the FGFR-3 and VEGF pathways, as well as two new monoclonal antibodies, enfortumab vedotin and sacituzumab govitecan.

Bladder Cancer and Immunotherapy

Posted by Daniel P. Petrylak, MD | Apr 2019

Daniel P. Petrylak, MD, reviews data regarding currently-approved immunotherapy agents for bladder cancer in first- and second-line settings. He advocates for future research regarding immunotherapy-based combinations, as well as investigating immunotherapy in earlier stages of the disease.

Immunotherapy for PCa: Where Do We Go From Here?

Posted by Daniel P. Petrylak, MD | Mar 2019

Daniel P. Petrylak, MD, discusses patient selection for currently-approved immunotherapies for prostate cancer, especially in patients with microsatellite instability. He also emphasizes the importance of utilizing immunotherapy early in the disease course.

Immunotherapy for Castration Resistant Prostate Cancer

Posted by Daniel P. Petrylak, MD | Nov 2018

Daniel P. Petrylak, MD, provides a brief update on data regarding sipuleucel-T for castration resistant prostate cancer (CRPC), as well as pembrolizumab for microsatellite instability (MSI) -high metastatic prostate cancer patients.

The Role of Targeting DNA Repair Mutations in Advanced Prostate Cancer with PARP Inhibitors

Posted by Daniel P. Petrylak, MD | Oct 2018

Daniel P. Petrylak, MD, provides a brief update on clinical trials evaluating therapies that target DNA repair mutations in castration resistant prostate cancer (CRPC) patients, including poly (ADP-ribose) polymerase (PARP) inhibitors, agents that exploit hypoxia-inducing BRCAness, and next generation anti-androgens.